Back to top
more

Phreesia (PHR)

(Delayed Data from NYSE)

$21.19 USD

21.19
262,142

-1.59 (-6.98%)

Updated Aug 7, 2024 04:00 PM ET

After-Market: $21.20 +0.01 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 43% (107 out of 250)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's What Key Metrics Tell Us About Phreesia (PHR) Q3 Earnings

by Zacks Equity Research

The headline numbers for Phreesia (PHR) give insight into how the company performed in the quarter ended October 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Phreesia (PHR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Phreesia (PHR) delivered earnings and revenue surprises of 19.44% and 2.56%, respectively, for the quarter ended October 2023. Do the numbers hold clues to what lies ahead for the stock?

Phreesia (PHR) Surges 10.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

Phreesia (PHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Compared to Estimates, Phreesia (PHR) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Phreesia (PHR) give a sense of how the business performed in the quarter ended July 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Phreesia (PHR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Phreesia (PHR) delivered earnings and revenue surprises of 9.33% and 1.22%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About Phreesia (PHR) Rating Upgrade to Buy

by Zacks Equity Research

Phreesia (PHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

How Much Upside is Left in Phreesia (PHR)? Wall Street Analysts Think 27.26%

by Zacks Equity Research

The consensus price target hints at a 27.3% upside potential for Phreesia (PHR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Nextgen Healthcare (NXGN) Surges 6.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Nextgen Healthcare (NXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Should You Buy and Phreesia (PHR) Ahead of Earnings?

by Zacks Equity Research

Phreesia (PHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Olink Holding AB (publ) Sponsored ADR (OLK) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Olink Holding AB (publ) Sponsored ADR (OLK) delivered earnings and revenue surprises of 22.22% and 12.11%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Hims & Hers Health, Inc. (HIMS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 50% and 1.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Phreesia (PHR) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Phreesia (PHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Phreesia (PHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Phreesia (PHR) give a sense of how the business performed in the quarter ended April 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Phreesia (PHR) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Phreesia (PHR) delivered earnings and revenue surprises of 12.50% and 3.97%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?

Nextgen Healthcare (NXGN) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of 6.90% and 4.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Tivic Health Systems, Inc. (TIVC) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Tivic Health Systems, Inc. (TIVC) delivered earnings and revenue surprises of 0% and 27.69%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Homology Medicines (FIXX) delivered earnings and revenue surprises of 9.09% and 40.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Invitae (NVTA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Invitae (NVTA) delivered earnings and revenue surprises of 9.76% and 1.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CareCloud, Inc. (CCLD) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

CareCloud, Inc. (CCLD) delivered earnings and revenue surprises of 9.68% and 3.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Inspire Medical Systems (INSP) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inspire (INSP) delivered earnings and revenue surprises of 24.29% and 6.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Phreesia (PHR) delivered earnings and revenue surprises of 7.69% and 2.56%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?

Sonendo, Inc. (SONX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sonendo, Inc. (SONX) delivered earnings and revenue surprises of 45.45% and 5.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Cooper Companies (COO) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Cooper Companies' (COO) fiscal first-quarter results are likely to reflect segmental strength.

What's in Store for Patterson Companies (PDCO) in Q3 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal third-quarter results are likely to reflect an improvement at the Animal Health segment.

What Makes Phreesia (PHR) a New Buy Stock

by Zacks Equity Research

Phreesia (PHR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.